Diacylglycerol Metabolism and Signaling Is a Driving Force Underlying FASN Inhibitor Sensitivity in Cancer Cells
ACS Chemical Biology
Oncology
Initial report of a first-in-human study of the first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640
EORTC-NCI-AACR International Conference
Characterization of small-molecule FASN inhibitors in preclinical tumor models
AACR-NCI-EORTC International Conference
